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ABSTRACT
Objectives: To investigate the association between
rheumatoid arthritis (RA) and periodontitis with special
emphasis on the role of antirheumatic drugs in
periodontal health.
Design: Prospective follow-up study. Patients with
early untreated RA and chronic active RA were
examined at baseline and 16 months later. Controls
were examined once.
Settings and participants: The study was
conducted in Finland from September 2005 to May
2014 at the Helsinki University Hospital. Overall, 124
participants were recruited for dental and medical
examinations: 53 were patients with early disease-
modifying antirheumatic drug (DMARD) naїve RA
(ERA), 28 were patients with chronic RA (CRA) with
insufficient response to conventional DMARDs. After
baseline examination, patients with ERA started
treatment with synthetic DMARDs and patients with
CRA with biological DMARDs. Controls were 43 age-
matched, gender-matched and community-matched
participants.
Outcome measures: Degree of periodontitis (defined
according to the Center for Disease Control and
Prevention and the American Academy of
Periodontology). Prevalence of periodontal bacteria
(analysed from plaque samples), clinical
rheumatological status by Disease Activity Score,
28-joint count (DAS28), function by Health
Assessment Questionnaire (HAQ) and treatment
response by European League Against Rheumatism
(EULAR) criteria.
Results: Moderate periodontitis was present in 67.3%
of patients with ERA, 64.3% of patients with CRA and
39.5% of control participants (p=0.001). Further,
patients with RA had significantly more periodontal
findings compared with controls, recorded with
common periodontal indexes. In the re-examination,
patients with RA still showed poor periodontal health
in spite of treatment with DMARDs after baseline
examination. The prevalence of Porphyromonas
gingivalis was higher in patients with ERA with
periodontal probing depth ≥4 mm compared with
patients with CRA and controls. Antirheumatic
medication did not seem to affect the results.
Conclusions: Moderate periodontitis was more
frequent in patients with RA than in controls. Patients
with ERA and CRA exhibited poorer periodontal health
parameters when compared with controls. There was
no association between antirheumatic treatment and
periodontal parameters.
INTRODUCTION
Periodontitis is a complex chronic inﬂamma-
tory disease destroying tooth-supporting
tissues with multifactorial aetiology,1–3 and it
has been linked to diabetes, cardiovascular
disease, adverse pregnancy outcomes, other
diseases, such as chronic obstructive airways
disease, chronic kidney disease, cognitive
impairment, metabolic syndrome, some types
of cancer and rheumatoid arthritis (RA).4
Periodontal diseases are highly prevalent and
can affect up to 90% of the world population
with varying degree of disease severity.5
Manifestation of periodontitis may vary from
latent to active phases and the disease may
ﬁnally lead to loss of teeth. RA is a chronic
autoimmune disease with recurring disease
cycles destroying, if untreated, the cartilage
and bone in the joints and subsequently
leading to loss of function and mobility.6 The
pathogenesis of RA is still unknown but both
genetic and environmental factors are
involved.7–10 The triggering factors of the
disease are under current interest.11 To sup-
press active inﬂammation, the treatment of
RA consists of the use of conventional syn-
thetic disease-modifying antirheumatic drugs
Strengths and limitations of this study
▪ We included two well-characterised patient
groups with rheumatoid arthritis (RA).
▪ This was a prospective follow-up study.
▪ Patients with RA in this study represent well
Finnish patients with RA in general.
▪ The number of study participants was a limita-
tion of the study.
▪ We examined the control participants only once.
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(DMARDs), biological DMARDs and low-dose oral glu-
cocorticoids. Patients with RA have an increased risk for
infections. In addition, the treatments, especially bio-
logical DMARDs, used to suppress the activity of RA are
associated with increased risk of infections.12 13
Periodontitis seems to have an association with RA
and it has even been suspected to be a triggering factor
for RA eruption.14 15 Bacterial cultures from subgingival
pockets of patients with periodontitis have identiﬁed
increased proportions of bacteria, such as Porphyromonas
gingivalis, Bacteroides forsythus, Campylobacter rectus,
Selenomonas noxia, Prevotella intermedia, Fusobacterium nucle-
atum and Aggregatibacter actinomycetemcomitans.16 17 Recent
studies suggest an association of oral bacterial infections
and RA, most of which were evaluated by bacterial gene
identiﬁcation or serum titre measurement.14 18 19
Susceptibility to periodontitis and RA shares similar-
ities regarding genetic and other factors such as obesity,
smoking and socioeconomic status.20 21 Periodontitis
and RA are chronic inﬂammatory diseases with varying
activity due to imbalance in the immune-inﬂammatory
response; their severity and loss of function also increase
with disease duration.18 Furthermore, both diseases have
similarities in morphology and histopathology.22
Humoral immune response to oral bacteria has been
suggested to be linked to the pathogenesis of RA.23
However, RA typically presents in middle-aged women
whereas periodontitis affects patients of any age and
gender, even adolescents.24 RA is nevertheless an inﬂam-
matory autoimmune disease,9 while periodontitis is an
immune-inﬂammatory disease of bacterial origin.25
Most of the previous studies on periodontitis and RA
are cross-sectional and have focused on chronic RA
(CRA) with analysis of clinical signs of periodontitis, or
microbiological ﬁndings, and the treatment with
DMARDs has not been well characterised or not men-
tioned at all. Therefore, we aimed to study prospectively
periodontitis in well-characterised patients with RA
before and after therapy with ﬁrst synthetic DMARDs or
ﬁrst biological DMARD. We compared patients with
early untreated RA before and after treatment with syn-
thetic DMARDs and those with chronic active RA on syn-
thetic DMARDs before and after treatment with
biological DMARDs. We analysed the changes in peri-
odontal and microbiological ﬁndings with respect to
antirheumatic therapy during a follow-up. The hypoth-
esis was that there indeed is an association between RA
and periodontitis and that RA treatment affects peri-
odontal disease.
METHODS
Study design
This was a prospective follow-up study on three groups
of participants: (1) patients with early DMARD naïve RA
(ERA), (2) patients with CRA with inadequate response
to synthetic DMARDs (CRA) and (3) population con-
trols. We included patients with RA aged 18–70 years.
Edentulous patients were excluded. The patients under-
went dental and rheumatological examinations before
and after the start of synthetic DMARDs and biological
DMARDs, respectively. The controls were examined
once. According to the classiﬁcation by Hartling et al,26
the study design is interrupted time series. The dental
and medical examinations were conducted from
September 2005 to May 2014; twice in patients with RA,
at baseline and after subsequent follow-up, mean 15.9
±6.1 months, and once, at baseline, in age-matched and
gender-matched controls living in the same geographical
region. One rheumatologist and one dentist examined
each patient independently and were blinded from each
other for the rheumatological and periodontal condi-
tion. Patients with RA were examined by the rheumatolo-
gist according to our hospital protocol in the
Department of Rheumatology in the Helsinki University
Hospital. The same dentist examined all the patients
throughout the study in the Department of Oral and
Maxillofacial Diseases, in the University of Helsinki. The
study was conducted according to the principles of the
Declaration of Helsinki. All patients and control partici-
pants gave written informed consent to participate in
the study.
Study population
Eighty-one patients with RA consisting 53 patients with
ERA and 28 patients with CRA with insufﬁcient response
to synthetic DMARDs (CRA) were recruited for clinical
dental and medical examinations from the Department
of Rheumatology of the Helsinki University Hospital.
Patients with RA were mostly women (85% of ERA and
82% of CRA group), with a mean age (±SD) 51±15 years
in ERA and 52±11 years in CRA cases. Patients with ERA
had suffered from the RA symptoms for a mean of 10.4
±17.1 months, and patients with CRA for 176
±116.8 months, respectively. We recruited 43 age-
matched and gender-matched control participants living
in the same geographical area with the mean age of 56
±13 years. Among them, 88% were women. The controls
had been recruited using Statistics Finland, the national
population database. During the study one patient with
CRA died, two patients with ERA moved away and one
patients with CRA and four ERA cases did not partici-
pate in the follow-up study because of personal reasons
(see ﬁgure 1).
Clinical dental examinations
All participants were examined at the Department of
Oral and Maxillofacial Diseases, in the University of
Helsinki, Finland. The same dentist examined all the
patients throughout the study in the Department of
Oral and Maxillofacial Diseases, in the University of
Helsinki. Complete dental status was recorded clinically
with help of bite-wing X-rays. Natural teeth were exam-
ined. Third molars and dental implants were excluded.
Periodontal parameters were recorded according to the
WHO recommendations.27 Periodontal probing depth
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(PD) and clinical attachment loss (AL) were assessed at
four sites per tooth from every tooth excluding the third
molars. All sites with PD≥4 mm were recorded, as well as
PD with 5 mm and ≥6 mm, respectively. Number of
teeth with 5 mm PD was counted according to 0–1 and
≥2 teeth. Degree of periodontitis was deﬁned according
to the Center for Disease Control and Prevention and
the American Academy of Periodontology (CDC/
AAP)28 In brief, severe periodontitis was deﬁned as two
or more teeth with AL≥6 mm at interproximal sites and
one or more teeth with PD≥5 mm at interproximal sites.
Moderate periodontitis was diagnosed when two or
more teeth with AL≥4 mm at interproximal sites or two
or more teeth with PD≥5 mm at interproximal sites were
detected. Mild periodontitis was diagnosed as ≥2 inter-
proximal sites with AL≥3 mm and ≥2 interproximal sites
with PD≥4 mm (not on the same tooth) or one site with
PD≥5 mm.29 ‘No periodontitis’ was recorded when the
criteria for severe, moderate or mild disease were not
fulﬁlled. Visible Plaque Index (VPI) and Bleeding on
Probing (BOP) were reported as percentages (positive
sites/all sites). Periodontal Inﬂammatory Burden Index
(PIBI) was calculated.30 Number of teeth was also calcu-
lated. In the total number of teeth third molars and
dental implants were excluded.
Periodontal bacteria
Subgingival plaque samples were taken for analysing peri-
odontal bacteria A. actinomycetemcomitans, P. gingivalis, P.
intermedia, Tannerella forsythia, Parvimonas micra and
C. rectus. Samples were pooled from the four to six deepest
periodontal pockets at baseline and from the patients with
RA again 1 year later. By sampling, sterile paper points
were inserted in each chosen periodontal pocket. The
paper points were then immediately transferred into a
tube containing viability-maintaining microbiostatic
medium, anaerobically prepared (Viability Medium
Goteborg Aga (VMGA) III) containing 5% bacto gelatine,
0.05% thione E-peptone, 0.2% washed Bacto Agar, 0.05%
thioglycolic acid, 0.05% L-cysteine-HCL, 1.0% Na glycero-
phosphate, 0.0005% phenylmercuric acetate, 0.0003%
methylene blue, 0.024% CaCl2 6H20, 0.042% KCl, 0.1%
NaCl, 0.01% MgSO4 7H2O. The samples were delivered
for microbiological analyses in our hospital laboratory
within 6 hours after sampling.
Medical examinations
Patients with RA were examined by a rheumatologist
according to our hospital protocol. The number of
swollen (66 joint count and 28 joint count) and tender
(68 joint count and 28 joint count) joints were recorded.
The patient’s global assessment of disease activity (PGA)
was based on a 100 mm visual analogue scale. Disease
Activity Score (DAS28) was calculated from the number
of tender and swollen joints (28-joint count), PGA and
erythrocyte sedimentation rate (ESR).31
Medication in the case of patients with early untreated
RA was introduced by the rheumatologist examining the
patient. Medication in the case of patient with CRA was
planned by the treating physician at the Department of
Rheumatology. In each case, the treatments were started
after the dental examination. The medications used by
the patients during follow-up were collected from the
patient ﬁles and by asking the patients during the
follow-up examination.
Laboratory measurements
Blood samples were analysed for plasma rheumatoid
factor (RF) by immunoturbidimetric assay (Roche/
Hitachi Modular P. Roche Diagnostics, Mannheim,
Germany), normal <14 IU/mL, plasma C reactive
protein (CRP) by immunoturbidimetric assay (Roche/
Hitachi Modular P. Roche Diagnostics, Mannheim,
Germany), normal <3 mg/L, ESR by automatic modiﬁed
Westergren method of EDTA blood diluted with citrate.32
Serum antinuclear antibody (ANA) was measured by the
Figure 1 Study protocol. CRA,
chronic rheumatoid arthritis; ERA,
early rheumatoid arthritis; RA,
rheumatoid arthritis.
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indirect immunoﬂuorescence technique on a HEp-2 cell
substrate (Inova Diagnostics, San Diego, California, USA).
The serum was initially screened at a 1:80 dilution, and
positive samples were further diluted to 1:160, 1:320,
1:640, 1:1280 and 1:5120. A titre of 1:320 or higher was
considered a positive result.
Antirheumatic treatment
After the baseline examinations, patients with ERA
started treatment with synthetic DMARDs comprising
methotrexate (MTX), leﬂunomide (LEF), sulfasalazine
(SSZ) and hydroxychloroquine (HCQ) either as mono-
therapy or in different combinations. Monotherapy was
used in 37.0% of patients with ERA (mostly MTX, two
patients had LEF), double DMARD therapy (MTX+SSZ,
MTX+HCQ, SSZ+HCQ or combinations with LEF) in
39.1% and triple DMARD therapy (MTX+SSZ+HCQ) in
19.1% of patients with ERA. In addition, low-dose
(≤10 mg prednisolone) oral glucocorticoids were started
in 28.3% of the patients with ERA. CRA cases started
biological DMARDs consisting of tumour necrosis factor
α (TNF-α) inhibitors (such as adalimumab in 9/27
(33.3%) of patients with CRA, etanercept in 17/27
(63.0%), golimumab in 2/27 (7.4%) and certolizumab
pegol in 1/27 (3.7%) of patients with CRA) or
non-TNF-α biologicals such as interleukin-1 inhibitor
(anakinra in 1/27 (3.7%) of patients with CRA) or
anti-B-cell agent (rituximab in 2/27 (7.4%) of patients
with CRA) mainly combined with MTX, 3 patients with
CRA had LEF. Different biological DMARDs were used
during the follow-up; in brief TNF-α inhibitor was used
in 85.2% of patients with CRA and non-TNF-α biologi-
cals in 7.4%, respectively. Low-dose prednisolone was
used by 74.1% patients with CRA. Intra-articular gluco-
corticoid injections and non-steroidal anti-inﬂammatory
drugs (NSAIDs) were used if needed to improve physical
function and quality of life.
Questionnaires
All the study participants ﬁlled out a structured ques-
tionnaire. Questions concerned general health and sys-
temic medication, education, health habits (smoking,
use of alcohol) as well as daily oral hygiene habits,
dental visits, self-assessed oral health and oral symptoms.
The questionnaire is a standard form at our clinic, and
used in several other studies.33 34
Statistical methods
The results are given as medians with IQRs (25–75%;
non-parametric distribution) or in means with SDs
(parametric distribution). Continuous variables were
compared between groups with analysis of variance and
Student’s t-test when possible, or non-parametric
Kruskal-Wallis and Mann-Whitney tests when comparing
independent samples. The baseline and follow-up values
were analysed with non-parametric Wilcoxon test com-
paring related samples. Categorical variables were com-
pared between the groups with χ2 test and between
baseline and follow-up values with McNemar’s test.
Binary logistic regression model was performed to estab-
lish odds for periodontitis according to variables such as
RA (early and chronic), tooth brushing, smoking,
gender and age. Statistical analyses were performed with
SPSS V.22 and p<0.05 was considered statistically
signiﬁcant.
RESULTS
RF was present in 79.2% of patients with ERA, 69.2% of
patients with CRA and in 3% of control individuals
(p<0.001). CRA participants had suffered from RA for a
mean of 176±116.8 months while the duration of disease
in patients with ERA was 10.4±17.1 months (p<0.001). At
baseline, ESR values were in median (IQR 25–75%) 20
(11–34) mm/hour in ERA, 20 (9–46) mm/hour in CRA
and 2 (2–10) mm/hour in the control group (p<0.001).
CRP values were 6 (3–14) mg/L in ERA, 18 (5–30) mg/L
in CRA and 2 (2–3) mg/L in the control group
(p<0.001), respectively.
Patients with RA had a history of hypertension, thyroid
disease, bronchial asthma, depression, cancer and dia-
betes as comorbidities. Compared with patients with
CRA and controls, the patients with ERA had more
often asthma (19% vs 0% in CRA, 5% in controls
(p=0.046)).
There were no statistically signiﬁcant differences
between the study participants with respect to age,
gender, smoking, alcohol use and level of education.
Background characteristics of the study groups are given
in more detail in table 1.
Self-reported oral health habits are given in table 2.
Control participants reported better oral hygiene habits,
especially more frequent approximal tooth cleaning,
when compared with patients with RA. At baseline, the
patients with RA reported having received less periodon-
tal treatments than controls, but in the re-examination
mean 16 months later the number of patients with RA
having periodontal treatment increased. The speciﬁc
determination of profession (hygienist, dentist, peri-
odontist) for periodontal treatment was not available
from the patients’ questionnaire.
Periodontal status parameters are given in table 3.
Periodontal ﬁndings in patients with RA differed signiﬁ-
cantly from the corresponding control cases in values of
VPI, BOP, PD≥4 mm, AL<3 mm, ≥3 mm<5 mm,
AL≥5mm and PIBI. Sixty seven per cent of the patients
with ERA and 64% of the patients with CRA had moder-
ate periodontitis at the time of entry to the study. In the
controls, the corresponding frequency was 39.5% as
given in table 3. CRP values in patients with ERA with
periodontitis (mild, moderate or severe) were in median
with IQR 6 (3–14) mg/L, in CRA participants with peri-
odontitis 17 (5–30) mg/L and in controls 2 (2–2) mg/L
(p<0.001) at baseline. However, in ERA cases with severe
periodontitis CRP values were 7 (3–15) mg/L, in
patients with CRA with severe periodontitis CRP values
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32 (21–42) mg/L and in the one control patient with
severe periodontitis 2 mg/L (p=0.029), respectively. At
follow-up examination, the periodontal status in patients
with RA was similar to the baseline.
Table 4 gives results from the cultivation of the peri-
odontal bacteria. At baseline periodontal bacteria were
more frequently detected in the patients with ERA com-
pared with patients with CRA, and after the follow-up,
the prevalence of periodontal bacteria in CRA group
was further diminished. In RA, P. gingivalis was observed
only in patients with ERA (p=0.043, table 4).
Figure 2 shows the results for P. gingivalis in the parti-
cipants who had PD≥4 mm. The culture for P. gingivalis
was positive in 11 participants (21.2%) in the ERA
group at baseline, compared with 3 participants (7.0%)
in the controls (p=0.009). In patients with CRA no
P. gingivalis-positive cases were found.
In patients with ERA, synthetic DMARDs were insti-
tuted ﬁrst after the clinical and dental examinations.
There were no statistically signiﬁcant changes in the
periodontal parameters between baseline and follow-up
examination (table 3). The patients with CRA examined
at baseline continued their baseline synthetic DMARD
(s) on which a biological DMARD was added on after
the baseline examination. Despite the biological
DMARD, no statistically signiﬁcant difference was found
in the periodontal parameters either in the patients with
CRA during the follow-up (table 3).
Of periodontopathic bacteria, P. gingivalis was less fre-
quently cultivated in patients with ERA at follow-up
examination, but with respect to other microbes, there
were no statistically signiﬁcant chances during the
follow-up (table 4).
After multivariate analysis for odds of periodontal
disease, age, gender, smoking and tooth brushing were
not statistically signiﬁcantly associated with periodontitis.
Signiﬁcant association was observed between CRA versus
controls, OR 5.3 (95% CI 1.1 to 25.6; p=0.044) and ERA
versus controls, OR 3.6 (95% CI 1.1 to 11.6; p=0.036).
Figures are given in table 5.
DISCUSSION
Periodontal health in RA
The main result in our study was that periodontal health
indeed was poorer in patients with RA in general com-
pared with population controls. Nearly 80% of patients
with ERA and 85% of patients with CRA suffered from
periodontitis vs 40% of controls at the baseline of this
study. These ﬁndings conﬁrmed earlier observations by
Wolff et al,35 and Ranade and Doiphode.36 The poorer
periodontal health could be the result of a weakened
immune defence in the host due to RA and further,
increase in systemic inﬂammation may initiate or
enhance the severity of periodontitis as pointed out by
Payne et al.37 Periodontitis in turn may have an impair-
ing inﬂuence on RA treatment response. Although our
results are based only a limited number of patients with
RA, they can be applied to Finnish patients with RA in
general, as our study populations are in line with two
Table 1 Background characteristics of the study groups at baseline
ERA (N=53) CRA (N=28) Controls (N=43) p Value
Women, N (%) 45 (85) 23 (82) 38 (88) 0.758
Age (years), mean±SD 51±15 52±11 56±13 0.160
Number of teeth, median (IQR) 27 (23–28) 27 (22–28) 27 (25–28) 0.628
Rheumatoid factor present (%) 42 (79.2) 18 (69.2) 3 (8.1)* <0.001
Disease duration (months), mean±SD 10.4±17.1 176±116.8 <0.001†
ESR (mm/hour), median (IQR) 20 (11–34) 20 (9–46) 2 (2–10)* <0.001
CRP (mg/L), median (IQR) 6 (3–14) 18 (5–30) 2 (2–3)* <0.001
DAS28, median (IQR) 4.0 (3.2–4.8) 4.1(3.0–4.9) 0.974
Education, N (%)‡
Lower 20 (37.7) 9 (36.0) 16 (61) 0.174
Secondary 27 (50.9) 12 (48.0) 6 (23.1)
Higher 6 (11.3) 4 (16.0) 4 (15.4)
Smoking, N (%)
Never 35 (66.0) 23 (82.1) 36 (83.7)
Former 7 (13.0) 2 (7.0) 1 (2.0)
Current 11 (21.0) 3 (11.0) 6 (14.0) 0.197
Alcohol use, N (%)
Seldom/none 28 (52.8) 12 (42.9) 13 (30.2)
Monthly/weekly 25 (47.2) 16 (57.1) 30 (69.8) 0.084
*N=37, missing data from six control participants, no visit to laboratory.
†p value obtained by non-parametric Kruskal-Wallis test comparing patients with ERA and CRA.
‡Missing data: 3 patients with CRA and 17 control participants for unknown reasons.
p Values by cross-tabulating with χ2 across the study groups.
CRA, chronic rheumatoid arthritis; CRP, serum C reactive protein level; DAS28, Disease Activity Score (28-joint count); ERA, early
rheumatoid arthritis; ESR, erythrocyte sedimentation rate; N, number of patients.
Äyräväinen L, et al. BMJ Open 2017;7:e011916. doi:10.1136/bmjopen-2016-011916 5
Open Access
group.bmj.com on April 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
recent reports from Finland. Rannio et al38 described all
patients with DMARD-naïve early RA (n=310) treated at
Jyväskylä Central Hospital rheumatology outpatient clinic
between 2008 and 2011. The centre covers rheumatology
care in the healthcare district with a population of
275 000. The demographic data of our patients with ERA
are comparable with those of the Jyväskylä cohort: mean
age 51 vs 60 years, women 81% vs 69%, duration of symp-
toms 10 vs 6 months, disease activity (DAS28) 4.0 vs 4.3.
As to the patients with CRA starting biological treatments,
we can compare our patients with CRA with those
reported from the National Register for Biologic
Treatment in Finland, which is a prospective cohort study
designed to monitor the effectiveness and safety of bio-
logical drugs in the treatment of rheumatic diseases. The
register covers about 70% of patients with RA treated with
biologics in Finland. Recently, Aaltonen et al39 reported
data collected from year 2003 onwards from this register.
The demographic data of our patients with CRA are com-
parable with those reported from the The Finnish
Register of Biological Treatment (ROB-FIN) registry:
mean age 52 vs 54 years, women 82% vs 79%, disease dur-
ation 14.6 vs 11 years, disease activity (DAS28) 4.1 vs 4.4
before the start of biological DMARD.
RA and periodontitis
An association between RA and periodontitis has been
suggested in several earlier studies.19 40–44 Of special
interest is that patients with early untreated RA had even
worse periodontal health compared with patients with
CRA, and further patients with RA both in early and
chronic stages suffered more frequently particularly
from moderate periodontitis when compared with popu-
lation controls in our study. The frequencies of peri-
odontitis in RA and control populations vary from study
to study. According to a recent review with meta-analysis,
the risk for periodontitis in RA versus controls is 1.13.45
The prevalence of periodontitis in the US population
aged over 30 years is 47%. The risk factors include
smoking, age, dental hygiene, minority status and socio-
economic status.46
Many authors, such as Loos,47 have suggested that
periodontal lesions may be the origin for daily bacter-
aemia and even raise systemic inﬂammation reﬂected in
markers such as CRP. In our study, patients with CRA
with severe periodontitis had higher CRP values com-
pared with corresponding ERA participants.
Interestingly, during the follow-up, no improvement
could be observed in periodontal status among the
patients with RA in either group.
RA and P. gingivalis
An association between infection at early arthritis phase
and the subsequent development of chronic rheumatic
complications has been discussed previously as reviewed
by Leirisalo-Repo.48 The presence of P. gingivalis in
patients with ERA, as observed in our study among the
patients with PD≥4 mm, may be a combining link
between periodontal disease and RA. Rutger Persson49
suggested that P. gingivalis infection through citrullina-
tion has a role in RA. And further, Mikuls et al50
reported that periodontal inﬂammation with P. gingivalis
Table 2 Self-reported oral health habits during the study
Baseline Follow-up
ERA (N=53) CRA (N=28)
Controls
(N=43)
p
Value*
ERA
(N=47)†
p
Value‡
CRA
(N=26)†
p
Value‡
Tooth brushing
Twice a day,
N (%)
35/53 (66.0)b 22/28 (78.6)a b 38/43 (88.4)a 0.035 37/47 (78.7) 00.125 20/25 (80.0) 1.000
Once a day or
less, N (%)
18/53 (34.0)b 6/28 (21.4)b 5/43 (11.6)a 10/47 (21.3) 5/25 (20.0)
Approximal
teeth cleaning,
N (%)
28/53 (52.8)a 15/28 (53.6)a 34/43 (79.1)b 0.018 28/47 (59.6) 1.000 15/25 (60.0) 0.250
Dental
appointments
<2 years, N (%)
43/53 (81.1)b 28/28 (100)a 41/43 (95.3)a 0.009
Dental treatment, N (%)
Periodontal 10/53 (18.9)a 4/28 (14.3)a 28/43 (65.1)b 0.000 21/46 (45.7) 0.001 11/25 (44.0) 0.109
Restorative
fillings
27/53 (50.9)b 21/28 (75.0)a 21/43 (48.8)b 0.063 22/46 (47.8) 0.424 10/25 (40.0) 0.004
*The p values are based on cross-tabulation with χ2-test.
†At ERA group six drop-outs, at CRA group three drop-outs for personal reasons.
‡ERA and CRA are compared at baseline and follow-up, p value by non-parametric McNemar’s test, related samples.
The figures are frequencies (N=number of patients) with percentages.
a bEach subscript letter denotes a subset of study group categories whose column proportions do not differ significantly from each other at the
0.05 level.
CRA, chronic rheumatoid arthritis; ERA, early rheumatoid arthritis.
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Table 3 Periodontal parameters at baseline and after follow-up in study groups
Baseline Follow-up Baseline Follow-up
ERA N=52 ERA N=46 p Value* CRA N=28 CRA N=26 p Value* Controls N=43 p Value†
Medication‡
DMARD monotherapy 0 17/46 (37.0%) 8/28 (28.6%) 0
Double DMARD therapy 0 18/46 (39.1%) 11/28 (39.3%) 0
Triple DMARD therapy 0 9/46 (19.6%) 7/28 (25.0%) 0
DMARD(s)+TNF inhibitor 0 0 0 23/27 (85.2%)
DMARD(s)+non-TNF inhibitor 0 0 0 3/27 (11.1%)
Periodontal degree, N (%)§
Mild 0 1 (2.2) 0.297 2 (7.1) 1 (4.0) 0.398 1 (2.3) 0.001
Moderate 35 (67.3) 34 (73.9) 8 (64.3) 14 (56.0) 17 (39.5)
Severe 6 (11.5) 5 (10.9) 4 (14.3) 3 (12.0) 1 (2.3)
Number of teeth 27 (23–28) 27 (22–28) 0.024 27 (22–28) 27 (22–28) 0.317 27 (25–28) 0.628
VPI per cent sites, median (IQR) 12 (5–25) 8 (4–20) 0.076 9 (5–19) 8 (3–19) 0.467 5 (2–11) 0.020
BOP per cent sites, median (IQR) 15 (10–26) 13 (6–21) 0.124 9 (5–19) 8 (3–22) 0.903 4 (2–8) 0.000
PD≥1 sites with ≥4mm, N (%) 45 (86.5) 43 (95.6) 0.083 25 (89.3) 21 (84.0) 0.564 28 (65.1) 0.013
0–1 site with ≥6 mm 49 (94.2) 43 (95.6) 0.564 24 (85.7) 22 (88.0) 0.317 42 (97.7) 0.131
≥2 sites with ≥6 mm 3 (5.8) 2 (4.4) 0.366 4 (14.3) 3 (12.0) 1.000 1 (2.3) 0.067
<2 teeth with ≥5 mm 39 (75.0%) 37 (80.4%) 23 (82.1%) 21 (80.8%) 40 (93.0%)
≥2 teeth with ≥5 mm 13 (25.0%) 9 (19.6%) 5 (17.9%) 5 (19.2%) 3 (7.0%)
AL<3 5 (9.6) 3 (6.7) 1.000 2 (7.1) 5 (20.0) 0.083 14 (32.6) 0.004
≥3<5 N (%) 47 (90.4) 42 (93.3) 1.000 26 (92.9) 20 (80.0) 0.083 29 (67.4) 0.004
≥5 22 (42.3) 21 (46.7) 0.257 10 (35.7) 8 (32.0) 0.317 8 (18.6) 0.045
PIBI, median (IQR) 10 (3–18) 9 (9–19) 0.907 5 (3–15) 4 (1–16) 0.856 1 (0–3) 0.000
In VPI and BOP index used 4 sites at every tooth.
§Definition for degree of periodontal disease according to the Center for Disease Control and Prevention and the American Academy of Periodontology (CDC/AAP; Page and Eke, 2007),8
mild periodontitis.29
*p Value by non-parametric Wilcoxon test comparing related samples at baseline and follow-up examination.
†p Value by cross-tabulation with χ2 comparing all study groups at baseline p value by non-parametric Kruskal-Wallis test.
‡DMARD monotherapy: mostly MTX, 2 patients had LEF; double therapy: MTX+SSZ, MTX+HCQ, SSZ+HCQ, or combinations with LEF; triple therapy: MTX+SSZ+HCQ; TNF inhibitor:
adalimumab in 9/27 (33.3%) patients with CRA, etanercept in 17/27 (63.0%), golimumab in 2/27 (7.4%) and certolizumab pegol in 1/27 (3.7%) patients with CRA; non-TNF-α biologics such as
interleukin-1 inhibitor (anakinra in 1/27 (3.7%) patient with CRA) or anti-B-cell agent (rituximab in 2/27 (7.4%) patients with CRA) mainly combined with MTX, 3 patients with CRA combined with
LEF.
AL, clinical attachment loss; BOP, Bleeding on Probing index; CRA, chronic rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; ERA, early rheumatoid arthritis ; HCQ,
hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N, number of patients; PD, periodontal pocket depth; PIBI, Periodontal Inflammation Burden Index; SSZ, sulfasalazine; TNF, tumour ;
necrosis factor; VPI, Visual Plaque Index.
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may modify the autoreactivity of RA. Bacterial culture
methods were used in this study for practical reasons,
being routine in the hospital laboratory. The association
of oral pathogens and periodontal activity might have
been higher if we had performed bacterial gene identiﬁ-
cation by real-time PCR or measured serum antibodies
to oral pathogens.
Antirheumatic medication and oral health
We also focused on the effect of the use of antirheumatic
medication on periodontal parameters. Therefore, we
included patients with early untreated RA at baseline.
After the examination, the patients started treatment
with synthetic DMARDs. Patients with CRA on the other
hand had suffered from the disease for about 14 years
and because of insufﬁcient response to synthetic
DMARDs, treatment with biological DMARDs was started.
Both synthetic and biological DMARDs were, if necessary,
combined with glucocorticoids or NSAIDs to suppress
the disease symptoms and to improve quality of life.
Recently, Beeraka et al51 reported an association
between the use of corticosteroids and higher levels of AL
and deepened periodontal pocket depth. We did not
observe any statistical difference in periodontal parameters
when comparing the baseline values to corresponding
ﬁgures after the mean 16 months follow-up in the ERA
and CRA groups. Our results on patients with ERA show
that periodontitis was observed in patients with RA already
in the early untreated phase and that conventional anti-
rheumatic treatment did not enhance the inﬂammation
or oral pathogenic microbes. This is in line with a previous
study, where MTX had no effect on dental status.52
Most studies on the association between treatment of
RA and severity of periodontitis have focused on bio-
logical DMARDs. A recent meta-analysis included four
reports on the effect of anti-TNF-α therapy in patients
with RA.53 In three out of the four reports, the treatment
was suppressing periodontal inﬂammation. Three more
publications have reported the suppressive effect of adali-
mumab, tocilizumab and rituximab on periodontitis.54–56
Contrary to these ﬁndings, periodontal parameters
remained stable during the 6-month treatment of 18
patients with RA with various anti-TNF-α therapies.57 Our
results show that biological DMARDs can be used in
patients with chronic active RA, as they do not worsen
periodontitis in these patients. In fact, there was a trend
for improvement in pocket depths in the CRA group.
However, while periodontitis does not usually need
pharmacological treatment, mechanical periodontal
treatment is required time after time.15
Health habits
Patients with RA in both groups reported poorer approx-
imal teeth cleaning and less periodontal dental
Table 4 Prevalence of periodontopathic bacteria at baseline and after follow-up in study participants with PD≥4mm
ERA
(N=46)
Baseline
CRA (N=25)
Baseline
Controls
(N=27) p Value*
ERA (N=43)
After
follow-up
CRA (N=21)
After
follow-up p Value†
Medication
DMARD monotherapy 0 8/28 (28.6%) 17/46
(37.0%)
0
Double DMARD therapy 0 11/28 (39.3%) 18/46
(39.1%)
0
Triple DMARD therapy 0 7/28 (25.0%) 9/46 (19.6%) 0
DMARD(s)+TNF
inhibitor‡
0 0 0 23/27
(85.2%)
DMARD(s)+non-TNF
inhibitors§
0 0 0 3/27 (11.1%)
Bacteria
A.a N (%) 4 (8.7%) 0 5 (18.5%) 0.074 2 (4.9%) 0 0.298
P.g 11 (23.9%) 0 2 (7.4%) 0.12 7 (17.1%) 0 0.043
P.i 15 (32.6%) 8 (33.3%) 10 (37.0%) 0.925 19 (46.3%) 5 (22.7%) 0.054
T.f 2 (4.3%) 1 (4.2%) 0 0.550 1 (2.4%) 1 (4.5%) 0.248
P.m 12 (26.1%) 6 (25.0%) 4 (14.8%) 0.514 10 (24.4%) 3 (13.6%) 0.329
C.r 2 (4.3%) 1 (4.2%) 0 0.550 3 (7.3%) 0 0.199
*p Values by cross-tabulation with χ2.
†p Values obtained with non-parametric Kruskal-Wallis test comparing independent samples (study groups: baseline−follow-up).
‡DMARD monotherapy: mostly MTX, 2 patients had LEF; double therapy: MTX+SSZ, MTX+HCQ, SSZ+HCQ, or
combinations with LEF; triple therapy: MTX+SSZ+HCQ; TNF inhibitor: adalimumab in 9/27 (33.3%) patients with CRA, etanercept in 17/27
(63.0%), golimumab in 2/27 (7.4%) and certolizumab pegol in 1/27 (3.7%) patients with CRA).
§Non-TNF-α biologics such as interleukin-1 inhibitor (anakinra in 1/27 (3.7%) patient with CRA) or anti-B-cell agent
(rituximab in 2/27 (7.4%) patients with CRA) mainly combined with MTX, 3 patients with CRA combined with LEF.
A.a, Aggregatibacter actinomycetemcomitans; C.r, Campylobacter rectus; CRA chronic rheumatoid arthritis; DMARD, disease-modifying
antirheumatic drug; ERA, early rheumatoid arthritis; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N number of
participants; PD, periodontal pocket depth; P.g, Porphyromonas gingivalis; P.i, Prevotella intermedia; P.m, Parvimonas micra; SSZ,
sulfasalazine; T.f, Tannerella forsythia; TNF, tumour necrosis factor.
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treatment compared with the population controls (see
table 2). Impaired oral health habits rather than wea-
kened immune defence could partly explain the differ-
ences in plaque accumulation and gingival
inﬂammation in patients with RA. This also reﬂects in
higher frequencies of VPI and BOP sites. However, the
weakened manual dexterity may have a role in oral
hygiene habits and thus these patients need special
attention in controlling oral hygiene with suitable indi-
vidual dental hygiene equipment combined with proper
periodontal treatment.
Against all expectations smoking or use of alcohol did
not seem to affect the results. This might be explained
by the fact that there is a decreased prevalence of
smoking among Finnish population in general.58
Strengths and limitations
The strengths of our study were the prospective
follow-up study of two well-characterised patient groups
with RA, the inclusion of control participants and the
homogeneous ethnicity of the population. All partici-
pants were from the population base of the Helsinki
University Hospital with more than 1.5 million inhabi-
tants. Our study patients are representative of the
patients with RA in Finnish population.38 39
The weakness was the fairly small number of patients
although we recruited all eligible patients during nearly
10 years (2005–2014). Furthermore, for practical
reasons, it was not possible to conduct follow-up examin-
ation in the controls.
To conclude, our study revealed poor periodontal
health in patients with early and CRA compared with
population controls. The periodontal parameters were
throughout higher in patients with early RA compared
with patients with RA with long disease history. We did
not observe any effect of synthetic or biological
DMARDs on the periodontal health parameters. Taking
Figure 2 Number of sites with PD≥4 mm and periodontopathic bacteria in RA groups and controls. The symbols show
individual participants with group medians denoted by horizontal lines. The groups were compared using Mann-Whitney test. The
dental plaque culture for Porphyromonas gingivalis was positive in 11 participants (21.2%) in the early RA group at baseline,
compared with 3 participants (7.0%) in the control group (p=0.009, χ2 test). The number of cases positive for P. gingivalis in
chronic RA group was 0. PD, periodontal pocket depth; RA, rheumatoid arthritis.
Table 5 Binary logistic regression for odds of
periodontitis
Variable OR (95% CI) p Value
Group
CRA 5.3 (1.1 to 25.6) 0.044
ERA 3.6 (1.1 to 11.6) 0.036
Controls 1
Brushing at least twice daily 0.7 (0.4 to 6.2) 0.657
Smoking (current) 0.3 (0.06 to 1.5) 0.134
Sex (male) 2.7 (0.3 to 24.5) 0.368
Age (per year) 1.1 (1.0 to 1.1) 0.011
CRA, chronic rheumatoid arthritis; ERA, early rheumatoid arthritis.
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into account the inﬂammatory burden of periodontitis
combined with the challenge of RA disease itself, these
patients should be under supervised oral health with
emphasis on periodontist. By offering these patients
relevant periodontal treatment, it is possible to reduce
oral inﬂammatory burden. This is of importance when
treating patients with autoimmune disease, such as RA,
and using biological DMARDs with increased risk of
infection as a side effect. However, the results with a
follow-up design should be conﬁrmed in a larger study
which includes control population, patients in the pre-
clinical phase of RA, those with early RA at the time of
diagnosis and those patients with RA who have failed
conventional DMARDs and are starting treatment with
biologicals. Thus, in future studies, periodontal health
parameters should be recorded and diagnosed if found,
in addition to targeting the RA treatment to remission
or to low disease activity; periodontitis should also be
actively treated and the treatment response should be
evaluated with respect to the activity of RA regularly.
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